You are here


Biotech firm shows the way onto the global stage

InvitroCue debuts on the ASX just four years after its birth; sales growth has doubled and is 'sustainable', says founder

Some members of the InvitroCue team - (from left) scientific development director of the cell-based unit Abhishek Ananthanarayanan, co-founder Dr Steven Fang and technical director of the pathology unit Xu Shuoyu. Co-founder Hanry Yu was absent.


SUCCESS stories in the Singapore life sciences sphere are few and far between, but InvitroCue, which targets profitability in seven years, could light the way for other homegrown biotechnology firms seeking to get on the global stage.

The biotech firm, a spin-off from the...